Making smart investment decisions in clinical research

A recent trial in rheumatoid arthritis found an inexpensive, but infrequently used, combination of therapies is neither inferior nor less safe than an expensive biologic drug. If the trial had been conducted over 10 years ago, arguably 100’s of millions of dollars since spent on biologics could have...

Descripción completa

Detalles Bibliográficos
Autores principales: Bansback, Nick, Keystone, Edward, O’Dell, James, Phibbs, Ciaran S., Hannagan, Keri, Brophy, Mary, Anis, Aslam
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2015
Materias:
Commentary
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4693420/
https://www.ncbi.nlm.nih.gov/pubmed/26712327
http://dx.doi.org/10.1186/s13063-015-1123-1
Descripción
Sumario:A recent trial in rheumatoid arthritis found an inexpensive, but infrequently used, combination of therapies is neither inferior nor less safe than an expensive biologic drug. If the trial had been conducted over 10 years ago, arguably 100’s of millions of dollars since spent on biologics could have been released to other, more effective treatments. Given the ever increasing number of trials proposed, this commentary uses the trial as an example to challenge payers and research funders to make smarter investments in clinical research to save potential future costs. Trial registration: NCT00405275, registered 29 November 2006

Ejemplares similares